Literature DB >> 3828964

Brain metastasis in patients with superior sulcus tumors.

R Komaki, S B Derus, C Perez-Tamayo, R W Byhardt, A Hartz, J D Cox.   

Abstract

During a 20-year period, from 1963 to 1983, 68 patients were treated for carcinoma of the lung presenting in the superior sulcus. Their ages ranged from 41 to 79 years (median, 56 years). Thirty-six patients had squamous cell carcinoma, 13 had adenocarcinoma, 14 had large cell carcinoma, two had small cell carcinoma, and three had clinical diagnosis only. All tumors were considered to be inoperable or unresectable and were treated with external irradiation alone. The 3-year disease-free survival was 25%. Brain metastasis developed in 23 patients (34%); the brain was the first site of metastasis in 16 patients (24%), five of whom eventually developed other sites of metastasis. The cumulative probability of brain metastasis was 53% at 3 years. Brain metastases were seen in ten patients (28%) with squamous cell carcinoma, five patients (38%) with adenocarcinoma, seven patients (50%) with large cell carcinoma, and one patient without a histocytologic diagnosis. The proportion of patients younger than 60 years (19/41, 46%) who developed brain metastasis was significantly greater than that for patients 60 years or older (4/27, 15%) (P less than or equal to 0.01). Nine of 11 patients with metastasis only to the brain died as a consequence of the intracranial disease 1 to 13 months (median, 6 months) after the diagnosis of brain metastases. The other two patients received therapeutic irradiation to the entire brain and survived longer than 5 days after the whole-brain irradiation: one died at 62 months of intercurrent disease, and the other is alive and well 129 months after diagnosis. The high probability of brain metastasis from superior sulcus tumors, regardless of histopathologic type and the frequency with which the brain is the only site of clinical failure, suggest that systematic prophylactic cranial irradiation could reduce the morbidity and perhaps even contribute favorably to the survival of these patients.

Entities:  

Mesh:

Year:  1987        PMID: 3828964     DOI: 10.1002/1097-0142(19870501)59:9<1649::aid-cncr2820590921>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Therapeutic modalities for Pancoast tumors.

Authors:  Panagopoulos Nikolaos; Livaditis Vasilios; Koletsis Efstratios; Alexopoulos Panagiotis; Prokakis Christos; Baltayiannis Nikolaos; Hatzimichalis Antonios; Kosmas Tsakiridis; Paul Zarogoulidis; Konstantinos Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Machairiotis; Theodora Tsiouda; Nikolaos Machairiotis; Athanasios Madesis; Georgios Vretzakis; Alexandros Kolettas; Dougenis Dimitrios
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

Review 2.  Treatment of pancoast tumors from the surgeons prospective: re-appraisal of the anterior-manubrial sternal approach.

Authors:  Haralabos Parissis; Vincent Young
Journal:  J Cardiothorac Surg       Date:  2010-11-04       Impact factor: 1.637

3.  Prophylactic Cranial Irradiation in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Karine A Al Feghali; Rami A Ballout; Assem M Khamis; Elie A Akl; Fady B Geara
Journal:  Front Oncol       Date:  2018-04-20       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.